More than 2 million units sold last year
Demand for skin care increases after the endemic
Dong-A Pharmaceutical establishes itself as a renowned brand for topical skin products
Following Noscanagel, Acnon Cream and Acrine Gel sales increase
Dong-A Pharmaceutical announced on the 26th that its acne treatment ‘Acnon Cream’ sold over 2 million units last year, ranking first in sales in the external acne treatment market for two consecutive years. It is assessed that Acnon Cream is leading a new revival in the market.
Acnon Cream is a pimple and acne treatment launched by Dong-A Pharmaceutical in July 2020. The main ingredients are said to be ibuprofen piconol, which has an anti-inflammatory effect and inhibits the production of lipolytic enzymes by acne bacteria, and isopropylmethylphenol, which has antibacterial effects and prevents the growth of acne bacteria. Dong-A Pharmaceutical explained that it contains about three times more isopropyl methyl phenol than existing pimple and acne treatments, helping to treat red and purulent acne.
An official from Dong-A Pharmaceutical said, “Due to the endemic disease, the use of masks has decreased and the demand for acne treatments has increased as skin care effects spread by word of mouth.” He added, “Acnon Cream led the market last year with sales increasing by about 99% compared to the previous year. “I did it,” he said.
Analysis suggests that lineup diversification also contributed to its popularity. Dong-A Pharmaceutical launched ‘Acrine Gel’, a treatment for millet acne (non-inflammatory acne), last year to respond to the increasing demand for acne treatments. It is a gel-type formulation containing 2% salicylic acid and tea tree oil, so it can be used hygienically and is convenient to store. Following Noscanagel and Acnon Cream, which are popular products in the acne treatment field, sales of Acrine Gel are said to be increasing.
A Dong-A Pharmaceutical official said, “Dong-A Pharmaceutical external skin products are receiving a lot of love from consumers, leading to a new revival,” and added, “We will continue to strive to introduce products that can easily resolve acne concerns in daily life.”
Kim Min-beom, Donga.com reporter mbkim@donga.com
Hot news now
Worried about the future? Then you will have fewer children
We live in uncertain times and many of us regularly worry about what the future will bring. And that not only has an impact on our night’s sleep, but also on whether or not we have children, it turns out.
A new study by Katya Ivanova, affiliated with Tilburg University, shows that people, especially women, who look at the future with a negative view have fewer children or at least postpone their desire to have children.
“It is special. In our Western world we live in an extremely prosperous and, if you look at the crime figures, safe times. Yet we do not trust that it will remain that way. Events that take place outside our national borders, wars for example, apparently influence the decisions we make here. We want to offer the generation after us a good future, and not all of us seem to trust that it will happen,” Ivanova said in an interview with AD.
Especially women
Katya Ivanova followed a representative group of Dutch people between 2010 and 2022, the women under 40 and the men under 45 years old at the start of the study. The analysis of this data shows that those who are concerned about the future and especially about the world in which the coming generations will have to grow up, had children significantly less often during the years of the study.
According to Ivanova, this difference is especially notable among women. Those who look very positively at the future even had 2.5 times greater fertility than those who think very negatively about the future.
However, some comments must be made about the study, especially because it is also possible that the participants simply postponed their choice for children to a later date and therefore ultimately grew older.
“But previous scientific research shows that people who postpone the choice of parenthood ultimately have fewer children than people who do not,” says Ivanova.
Related posts:
Personalized mRNA Vaccine for Melanoma – A Game Changer in Cancer Treatment
2024-04-26 09:32:00
When the COVID-19 virus outbreak hit, the world learned more about the mRNA vaccine. As the hope of preventing disease It is also the future of protecting populations against the deadliest disease, cancer.
Recently, the UK launched phase 3 clinical trials of the world’s first “personalized mRNA vaccine” against the deadliest form of skin cancer, melanoma.
Steve Young, 52, from Stevenage. He was one of the first patients to volunteer to test the new vaccine. He had skin melanoma. and just had a scalp tumor removed last August.
Vaccine mRNA-4157 (V940) It is designed to help the vaccine recipient’s immune system recognize and eliminate any remaining cancer cells. This means In theory, His cancer would not come back.
Doctors at University College London Hospital (UCLH) administer the vaccine in combination with another medicine, pembrolizumab. (Pembrolizumab), which helps the immune system kill cancer cells
The combination treatment trial is being led by Moderna, the company that developed the mRNA technology, and Merck Sharp & Dohme, a major drug developer.
Experts in other countries including Australia The same formula is also being tested on cancer patients. to gather further evidence and whether this treatment should be made more widely available.
Patients will receive 1 mg of the mRNA vaccine every 3 weeks for up to 9 doses and will receive 200 mg of pembrolizumab every 3 weeks (up to 18 doses) for approximately 1 year.
Vaccines are individualized. This means that the composition of the vaccine will change depending on each patient. Not the same at all
It is created to match the unique genetic signature of the patient’s tumor. And it works by instructing the body to make proteins or antibodies that attack only the targets or antigens present in these cancer cells.
UCLH researcher Dr Heather Shaw said the trial had potential as a treatment for melanoma patients. And it is being tested in other cancers, such as lung tumors. Bladder and kidneys
“It’s one of the most exciting things we’ve seen in years. It is created specifically for each patient. You cannot give the same vaccine to the next patient in line. I don’t think it’s going to work,” Shaw said.
She added: “These are very technical and carefully designed for the patient. »
The UK trial aims to recruit at least 60 to 70 patients at eight testing centers across the country. Patients participating in the trial must have had a high-risk skin cancer removed at least 12 weeks before vaccination. To get the best results
Steve Young said: “This trial gives me the opportunity to feel that I am really taking action against this invisible enemy… The analyzes show that I still have a chance. Cancer cells go undetected, so instead of waiting and hoping. it’s not coming back, I actually have the opportunity to get involved by putting on the boxing gloves and fighting it.
Phase 2 trial data released in December 2023 found that people with serious, high-risk tumors who received the vaccine in combination with pembrolizumab treatment were almost half (49%) more likely to die or see their cancer return within 3 years than those treated with pembrolizumab alone.
Dr Shaw said there was real hope that this treatment would be a “game changer”, especially as the treatment appears to have relatively tolerable side effects, such as fatigue, arm pain and other symptoms similar to those of a flu shot or COVID-19.
Compiled from BBC
1714139329
#England #begins #testing #mRNA #vaccine #treat #melanoma #skin #cancer #PPTVHD36
Related posts:
Personalized mRNA Vaccine for Melanoma – A Game Changer in Cancer Treatment